Clinical advances in biological therapy for generalized pustular psoriasis: a review
- Published on 02/12/2024
- Reading time: 4 min.
Chang-Yu Hsieh & Tsen-Fang Tsai *
Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
CONTACT Tsen-Fang Tsai mailto:tftsai@yahoo.com Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Zhongshan S. Rd., Zhongzheng Dist, Taipei 100, Taiwan (R.O.C.)
Abstract
Introduction In 2022, U.S. Food and Drug Administration (FDA) approved the first biologics, intravenous spesolimab, for acute flare of generalized pustular psoriasis (GPP). The drug works by blocking IL-36 signaling, the key pathway of GPP. Among the known mutations causing GPP, IL36RNmutations are most common, and the presence of IL36RNmutations had been found to affect the clinical manifestations and treatment response of GPP.
Areas covered...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Dermatology
Receive our newsletter to stay up to date with the latest news in Dermatology
